DKN-01 Gets Fast-Track Status for Gastric and GEJ Cancer
September 25th 2020The FDA has granted a fast track designation to DKN-01 for the treatment of patients with gastric and gastroesophageal junction adenocarcinoma whose tumors have high DKK1 expression, who have progressed on or after a fluoropyrimidine- and platinum-containing chemotherapy, and HER2/neu targeted therapy, if appropriate.
FDA Grants Priority Review to Crizotinib for Pediatric ALK-Positive ALCL
September 24th 2020The FDA has granted a priority review to a supplemental new drug application (sNDA) for crizotinib (Xalkori) in the treatment of pediatric patients with ALK-positive relapsed/refractory systemic anaplastic large cell lymphoma (ALCL), according to an announcement from Pfizer, Inc.
Molecularly-Guided Therapy Improves Outcomes in Kidney Cancer
September 22nd 2020Findings from the noncomparative, phase 2, biomarker-driven BIONIKK trial demonstrated clinical evidence to support the use of molecularly-directed frontline therapy as means to enrich responses in patients with metastatic clear cell renal cell carcinoma (ccRCC).
Surufatinib Shows PFS Benefit in Advanced Pancreatic NETs
September 21st 2020The novel VEGFR, FGFR, and CSF-1R inhibitor surufatinib yielded a statistically significant and clinically meaningful progression-free survival (PFS) benefit compared with placebo in patients with advanced pancreatic neuroendocrine tumors (pNETs), according to results from the randomized phase 3 SANET-p trial that were presented virtually during the 2020 ESMO Congress.
High-Risk Biology Associated With Poorer Outcomes in MCL
September 20th 2020Patients with mantle cell lymphoma (MCL) who have high-risk biology, including blastoid variant, a Ki-67 score of at least 30%, or high p53 expression, had a significantly shorter failure-free and overall survival (OS), according to results of a retrospective trial.
Novel Molecule Enhances Immunotherapy Response in CRC, According to Early Data
September 19th 2020The advent of immunotherapy has revolutionized multiple areas of cancer treatment, said Timothy Cragin Wang, MD, who added that the transformative potential of the modality has been mild at best in the field of colorectal cancer (CRC).
Christie Santure, B.S.N., RN, OCN, Wins CURE's 2020 Extraordinary Healer Award for Oncology Nursing
September 18th 2020At a virtual event Sept. 17, CURE® also named Elizabeth Farrat, B.S.N., RN, CCRN-K, the winner of its first-ever Finest Hour Award for selfless achievements in care during the COVID-19 pandemic.
Magrolimab Gets FDA Breakthrough Designation Status for MDS Treatment
September 16th 2020The FDA has granted a breakthrough therapy designation to magrolimab for the treatment of patients with newly diagnosed myelodysplastic syndrome (MDS), according to an announcement from Gilead Sciences, Inc.
EPI-7386 Gets Fast Track Designation for mCRPC Treatment
September 15th 2020The FDA granted a fast track designation to the highly-selective N-terminal domain inhibitor EPI-7386 for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who are resistant to standard-of-care options, according to an announcement from ESSA Pharma Inc.
FDA Approves Copper Cu 64 Dotatate Injection for Somatostatin Receptor-Positive NETs
September 10th 2020The FDA has approved copper Cu 64 dotatate injection (Detectnet) for the localization of somatostatin receptor–positive neuroendocrine tumors (NETs), according to an announcement from RadioMedix Inc. and Curium Pharma.
Atezolizumab Plus Paclitaxel in Breast Cancer: FDA Issues Safety, Efficacy Alert
September 8th 2020The FDA has issued an alert to professionals, investigators, and patients that the phase 3 IMpassion131 trial (NCT03125902) failed to show the effectiveness of atezolizumab (Tecentriq) plus paclitaxel in treatment-naïve patients with inoperable locally advanced or metastatic triple-negative breast cancer.
Stay Vigilant When Treating Cancer During the COVID-19 Pandemic
September 7th 2020The novel coronavirus disease (COVID-19) continues to impact the care of patients with metastatic renal cell carcinoma (mRCC) and other cancers in a multitude of ways, according to Toni K. Choueiri, MD, but those working in the field of oncology are rising up to the challenge by learning as much as possible about the virus to make the best treatment decisions possible for their patients.
Blinatumomab: New Standard of Care for Pediatric, High-Risk ALL
September 6th 2020Blinatumomab (Blincyto) monotherapy as consolidation therapy prior to allogeneic hematopoietic stem cell transplant (HSCT) resulted a significant improvement in event-free survival (EFS) and a lower risk of recurrence in children with high-risk B-cell precursor (BCP­)–acute lymphoblastic leukemia (ALL).